Gilead HSV Plan Could Transform Market Outlook

While the biotech world has focused for years on topics such as obesity, novel cancer therapies, and artificial intelligence, one of the sector’s greatest untapped opportunities could be unfolding in the background. Assembly Biosciences, Gilead’s partner in finding new therapies in virology, may be on the verge of an event that could permanently change the perception of the herpes simplex virus market and, consequently, the company’s valuation.

The imminent catalyst is the announced disclosure of the development and commercialization plan by pharmaceutical giant and global leader in virology, Gilead Sciences, regarding the long-acting drug candidates ABI-5366 and ABI-1179 – two agents that have shown results in clinical proof-of-concept trials that many observers describe as the strongest antiviral data ever documented for HSV. Gilead subsequently in-licensed both candidates, developed by Assembly Bio, at the end of last year.

The market underestimates the importance of HSV

Herpes simplex virus is one of the most common chronic viral infections in humankind.

Billions of people worldwide live with HSV-1 or HSV-2. In major Western markets alone, millions of patients suffer from recurrent genital or oral herpes. Despite this, relatively little has changed therapeutically in recent decades. The moderately effective acyclovir and related drugs continue to dominate the market.

This is precisely where the enormous opportunity lies.

If ABI-5366 and ABI-1179 can confirm their previous results, a new class of drugs could emerge for the first time, which not only drastically reduces outbreaks but also potentially reduces virus transmission.

This would transform the market from a symptomatic niche treatment into a broad prevention and suppression strategy.

Statements from Gilead speak volumes

It is particularly noteworthy how openly Gilead now speaks about HSV in professional and patient circles, while communication with the financial market remains silent.

For example, Gilead’s responsible development director Yoshihiko Murato explained at an event of the Herpes Cure Advocacy regarding the HSV portfolio licensed by Assembly:

We recognize the potential for Herpes Simplex Virus in general…We’re certainly very keen on expanding our virology portfolio…We will move as swiftly as possible…We are trying to explore all potential possibilities with these two assets…The public announcement that we made to in-license these assets is a testament to Gilead’s future-looking commitment to HSV…We look forward to share more development news in the near future.

For experienced biotech investors, such statements are remarkable

Gilead isn’t talking about a side project here. The company is discussing a potential new strategic pillar within its virology business, one that could become as important to the corporation in the long term as HIV. In fiscal year 2025, HIV revenues amounted to almost $21 billion. This represents approximately 72 percent of the corporation’s total product sales.

The upcoming development plan could change everything. The next major catalyst is the announced communication of the further development strategy. The plan is expected to be available by mid-year. It could happen at any time now.

The market is currently mainly expecting information on Phase 2 trials.

__

(Featured image by Melany via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in sharedeals.de. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.